Sector Expert: Ajay Tandon

SeeThruEquity

Image: Ajay Tandon

Ajay Tandon brings more than 15 years of experience in the financial service industry, and considerable experience advising, structuring transactions and raising capital for small-cap public and private enterprises to his role as chief executive officer and director of research at SeeThruEquity. Tandon cofounded Emissary Capital, a private investment firm focused on micro-cap investment banking. Previously, Tandon served as vice president of equity capital markets at Maxim Group LLC, a New York City-based, full-service investment banking firm. Prior to his role at Maxim, Tandon served as an executive for Dealogic plc, an analytics platform used by global and regional investment banks worldwide to help optimize performance and improve competitiveness. Tandon began his career in financial services as a management consultant with IBM Global Services, and earned his bachelor's degree from Cornell University.



Recent Interviews

Eight Ways to Leverage the Small-Cap Biotech Bull Market: Ajay Tandon and Jay Albany of SeeThruEquity (10/28/15)
BalanceMoneyandPills580

SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.

Huge Growth Delivered in Very Small Packages: SeeThruEquity's Ajay Tandon and Brandon Primack (10/30/14)
moneygiftbox580

Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very small companies. The paradox: The micro-cap space is where investors can find the tenbaggers. That disconnect and its attendant irony are not lost on SeeThruEquity's Ajay Tandon and Brandon Primack. In this interview with The Life Sciences Report, Tandon and Primack discuss four companies nurturing seeds of dramatic growth that could materialize in the wake of upcoming catalysts.

X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays (5/1/14)

SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise. In this interview with The Life Sciences Report, senior analyst Brandon Primack and the firm's CEO, Ajay Tandon, explain why they find this handful of small biotechs intriguing.

Recent Quotes

"INNV reported 99% top line growth for its second quarter."

— Ajay Tandon, SeeThruEquity (8/22/17)
more >

"INNV recently released robust top-line results in Q1/17; revenues rose by 865% to $2.2M in Q1/17 versus $0.2M in Q1/16."

— Ajay Tandon, SeeThruEquity (5/26/17)
more >

— Ajay Tandon, SeeThruEquity (11/16/16)
more >

"HOTR has an impressive management team."

— Ajay Tandon, SeeThruEquity (9/11/15)
more >

"CYP's pursuit of off-the-shelf commercialization of therapeutic MSCs could be a game-changer."

— Ajay Tandon, SeeThruEquity (9/2/15)
more >

"NPHC has demonstrated impressive growth by expanding its portfolio of high-margin products."

— Ajay Tandon, SeeThruEquity (7/10/15)
more >

"RESX has a well-experienced management team."

— Ajay Tandon, SeeThruEquity (7/8/15)
more >

"DMPI observed dose-limiting toxicity in its VAL-083 clinical trial."

— Ajay Tandon, SeeThruEquity (3/2/15)
more >



Due to permission requirements, not all quotes are shown.